Page 4 - Asco Gi News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Asco gi. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Asco Gi Today - Breaking & Trending Today

Opdivo-Chemo Combination Improves Survival in GI Cancers

Treatment with Opdivo and chemotherapy improved survival in patients with gastrointestinal cancers, compared with chemotherapy alone, according to a phase 3 trial. ....

Kohei Shitara , National Cancer Center Hospital , National Cancer Center Hospital East , Adding Opdivo , Frontline Chemo Boosts Survival , Asco Gi , Gastric Cancers ,

Tiragolumab Plus Atezolizumab and Chemotherapy Offers Survival Benefit Over Chemotherapy Alone in ESCC

Tiragolumab plus atezolizumab and chemotherapy led to significant survival improvements vs chemotherapy in patients with esophageal squamous cell carcinoma. ....

South Korea , Hong Kong , Baseline Patient , Secondary End Points , 2024 Gastrointestinal Cancers Symposium , Asco Gi , Esophageal Squamous Cell Carcinoma , Skyscraper 08 ,

Adding Opdivo to Frontline Chemo Boosts Survival in Advanced GI Cancers

Patients with advanced gastric cancers tended to have better survival outcomes when given Opdivo plus chemotherapy, compared to those who were given chemotherapy alone. ....

Ian Chau , Flatiron Health , Frontline Opdivo , Royal Marsden , Gastric Cancers , Asco Gi ,

FDA Grants Priority Review to TAS-102 Plus Bevacizumab for Refractory mCRC

The FDA has accepted for priority review the supplemental new drug application seeking the approval of trifluridine/tipiracil as a single agent or in combination with bevacizumab for use in select patients with refractory, metastatic colorectal cancer. ....

United States , European Union , North America , Cancers Symposium , Priority Review , Trifluridine Tipiracil , Tas 102 , Tas 102 Plus Bevacizumab , Colorectal Cancer , Sunlight Trial , Asco Gi , Gastrointestinal Cancers Symposium , Gastrointestinal Cancer , Supplemental New Drug Application ,